Lymphocytes armed to kill: how customised cell engineering advances immunotherapy

Posted: 4 April 2018 | | No comments yet

The immune system is now regarded as a powerful weapon in the war against cancer, and in the current era immune cells have become ‘living drugs’. This review article considers some of the key advances in immuno-oncology…

The idea that the immune system’s own power can be harnessed and redirected to detect and destroy cancer cells has become a reality in the last decade.

We have come a long way from William Coley’s early suspicions that a link might exist between the immune system and an anti-cancer effect when he first observed that patients with sarcoma experienced tumour regression following severe bacterial infections. Much later, by isolating tumour infiltrating lymphocytes (TILs), a direct relationship between cancer and the immune system was discovered, which permitted a greater understanding of cellular immunology and the molecular mechanisms underlying the immune response to cancer.

This knowledge led to a new therapeutic approach that resulted in many success stories, primarily in the treatment of melanoma. 

The rest of this article is restricted - login or subscribe free to access

DTR Issue 3 2021 MiniMagThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here